← Companies|Affinia Ther
Af

Affinia Ther

Waltham MAFounded 201950 employees
Private CapbiotechPrivateRare DiseaseNeurology
Platform: Synth AAV
Market Cap
N/A
All Drugs
3
Clinical Trials
6
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
AdagracapivasertibAFF-2604Approved3PeptideMALT1CD47iPompeDravet
MotavorutinibAFF-9229NDA/BLA2Fusion ProteinPRMT5CAR-T BCMAWMWet AMD
AFF-3518AFF-3518Phase 11Gene TherapyHER2JAK1/2iCeliacALS
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)
2025-12-28
Motavorutinib Ph3 Readout
Wet AMD
Past
2026-08-07
Motavorutinib Ph3 Readout
Wet AMD
Ph3 Readout
2027-10-20
Adagracapivasertib Ph3 Readout
Dravet
Ph3 Readout
2028-04-03
AFF-3518 Interim
PBC
Interim
2030-09-19
Adagracapivasertib Ph3 Readout
Pompe
Ph3 Readout
2031-12-25
Adagracapivasertib Ph3 Readout
Dravet
Ph3 Readout